ENTITY

BioAge Labs (BIOA US)

4
Analysis
Health Care • United States
BioAge Labs, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge Labs serves customers worldwide.
more
bullish•BioAge Labs
•09 Aug 2026 12:21

Primer: BioAge Labs (BIOA US) - Aug 2026

BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of...

Logo
88 Views
Share
•12 Dec 2024 10:24•Issuer-paid

Biopharma Week in Review - December 9, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BIOA discontinued...

Logo
376 Views
Share
bullish•BioAge Labs
•19 Sep 2024 23:27

BioAge Labs Launches IPO Roadshow, Seeks To Raise Up To $150M on the Nasdaq Exchange

GLP-1 biopharma company BioAge Labs will price its IPO in September. I have a positive view of initial public offering and expect a strong first...

Share
bullish•BioAge Labs
•18 Sep 2024 01:59

BioAge Labs IPO Preview: Investor Focus Has Turned To Azelaprag, A Huge Market Potential

California-based BioAge Labs files for an IPO and plans to raise capital for clinical trials of their lead compound, Azelaprag, in combination with...

Share
x